12 results
40-F
2023 FY
EX-99.1
IPA
ImmunoPrecise Antibodies Ltd
10 Jul 23
Annual report (Canada)
4:32pm
keep their workforce employed. Borrowers were eligible for full forgiveness if certain conditions were met. The Company was approved for a loan of US
40-F
2023 FY
EX-99.2
IPA
ImmunoPrecise Antibodies Ltd
10 Jul 23
Annual report (Canada)
4:32pm
potential and assembled workforce of BioStrand.
During the three months ended July 31, 2022, the Company recorded the right-of-use assets and lease
6-K
EX-99.2
IPA
ImmunoPrecise Antibodies Ltd
15 Dec 22
Current report (foreign)
8:00am
to the total fair value of net assets will represent the sales growth potential and assembled workforce of BioStrand.
During the three months ended July 31
6-K
EX-99.2
IPA
ImmunoPrecise Antibodies Ltd
14 Sep 22
Current report (foreign)
8:31am
and assembled workforce of BioStrand.
The fair value of the consideration transferred has been determined on a preliminary basis. The fair value
40-F
2022 FY
EX-99.1
IPA
ImmunoPrecise Antibodies Ltd
29 Jul 22
Annual report (Canada)
9:04am
in the United States to help businesses impacted by COVID-19 keep their workforce employed. Borrowers were eligible for full forgiveness if certain
40-F
EX-99.2
8dzxzvfuo2
29 Jul 22
Annual report (Canada)
9:04am
6-K
EX-99.2
3bu4zfsei8yuzq
16 Mar 22
FY22 Q3 6-K
8:00am
6-K
EX-99.2
8ya9r7ye
13 Dec 21
Ipa FY22 Q2 6-K
8:57am
6-K
EX-99.2
e8uc5nd3c4e im9g3
9 Sep 21
Ipa FY22 Q1 6-K Filing
8:28am
40-F
EX-99.3
0q85 h183awkes00ya6
28 Jul 21
Annual report (Canada)
8:01am
40-F
EX-99.1
eo3pnv7wz
28 Jul 21
Annual report (Canada)
8:01am
40-F
EX-99.2
okp09
28 Jul 21
Annual report (Canada)
8:01am
- Prev
- 1
- Next